CORRESP Filing
Pasithea Therapeutics Corp.
Date: May 1, 2025 · CIK: 0001841330 · Accession: 0001213900-25-038336
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-333
Letter
Re: Pasithea Therapeutics Corp. (the “Company”)
May 1, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (File No. 333-333-286889 )
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 12 p.m., Eastern Time, on May 5, 2025, or as soon as practicable thereafter.
The Company hereby authorizes James B. O'Grady of Lowerstein Sandler LLP, the Company's outside legal counsel, to orally modify or withdraw this request for acceleration.
Please call Mr. O’Grady at (646) 414-6849 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
PASITHEA THERAPEUTICS CORP.
Show Raw Text
CORRESP 1 filename1.htm May 1, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pasithea Therapeutics Corp. (the “Company”) Registration Statement on Form S-1 (File No. 333-333-286889 ) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 12 p.m., Eastern Time, on May 5, 2025, or as soon as practicable thereafter. The Company hereby authorizes James B. O'Grady of Lowerstein Sandler LLP, the Company's outside legal counsel, to orally modify or withdraw this request for acceleration. Please call Mr. O’Grady at (646) 414-6849 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, PASITHEA THERAPEUTICS CORP. By: /s/ Dr. Tiago Reis Marques Dr. Tiago Reis Marques Chief Executive Officer